These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29864700)
1. Design, synthesis and in vitro evaluation of heterobivalent peptidic radioligands targeting both GRP- and VPAC Lindner S; Fiedler L; Wängler B; Bartenstein P; Schirrmacher R; Wängler C Eur J Med Chem; 2018 Jul; 155():84-95. PubMed ID: 29864700 [TBL] [Abstract][Full Text] [Related]
2. Are heterobivalent GRPR- and VPAC Lindner S; Rudolf H; Palumbo G; Oos R; Antons M; Hübner R; Bartenstein P; Schirrmacher R; Wängler B; Wängler C Bioorg Med Chem Lett; 2021 Sep; 48():128241. PubMed ID: 34217827 [TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y₁)- and GRP-Receptors-An Improvement for Breast Cancer Imaging? Vall-Sagarra A; Litau S; Decristoforo C; Wängler B; Schirrmacher R; Fricker G; Wängler C Pharmaceuticals (Basel); 2018 Jul; 11(3):. PubMed ID: 29973529 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro and In Vivo Evaluation of Heterobivalent SiFA Cheng X; Hübner R; von Kiedrowski V; Fricker G; Schirrmacher R; Wängler C; Wängler B Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34200477 [TBL] [Abstract][Full Text] [Related]
6. Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor. Begum AA; Moyle PM; Toth I Bioorg Med Chem; 2016 Nov; 24(22):5834-5841. PubMed ID: 27670095 [TBL] [Abstract][Full Text] [Related]
7. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125 [TBL] [Abstract][Full Text] [Related]
8. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist. Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447 [TBL] [Abstract][Full Text] [Related]
9. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452 [TBL] [Abstract][Full Text] [Related]
10. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272 [TBL] [Abstract][Full Text] [Related]
11. Next Step toward Optimization of GRP Receptor Avidities: Determination of the Minimal Distance between BBN(7-14) Units in Peptide Homodimers. Fischer G; Lindner S; Litau S; Schirrmacher R; Wängler B; Wängler C Bioconjug Chem; 2015 Aug; 26(8):1479-83. PubMed ID: 26200324 [TBL] [Abstract][Full Text] [Related]
12. Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. Judmann B; Braun D; Wängler B; Schirrmacher R; Fricker G; Wängler C Pharmaceuticals (Basel); 2020 Jul; 13(8):. PubMed ID: 32751666 [TBL] [Abstract][Full Text] [Related]
13. Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells. Shrivastava A; Wang SH; Raju N; Gierach I; Ding H; Tweedle MF Bioorg Med Chem Lett; 2013 Feb; 23(3):687-92. PubMed ID: 23265893 [TBL] [Abstract][Full Text] [Related]
14. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139 [TBL] [Abstract][Full Text] [Related]
15. In Vitro Mouse and Human Serum Stability of a Heterobivalent Dual-Target Probe That Has Strong Affinity to Gastrin-Releasing Peptide and Neuropeptide Y1 Receptors on Tumor Cells. Ghosh A; Raju N; Tweedle M; Kumar K Cancer Biother Radiopharm; 2017 Feb; 32(1):24-32. PubMed ID: 28186846 [TBL] [Abstract][Full Text] [Related]
16. PESIN multimerization improves receptor avidities and in vivo tumor targeting properties to GRPR-overexpressing tumors. Lindner S; Michler C; Wängler B; Bartenstein P; Fischer G; Schirrmacher R; Wängler C Bioconjug Chem; 2014 Mar; 25(3):489-500. PubMed ID: 24533789 [TBL] [Abstract][Full Text] [Related]